Cancer prevalence, incidence, and mortality rates in Afghanistan in 2020: A review study.
Afghanistan
cancer
incidence
mortality
prevalence
risk factors
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
17
06
2023
received:
26
04
2023
accepted:
17
07
2023
medline:
7
9
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
ppublish
Résumé
Afghanistan is in an epidemiological transition, as cancer is the second leading cause of mortality due to non-communicable diseases. This study is the first to provide a comprehensive perspective on the overall cancer situation in Afghanistan by discussing the top five most common cancers, their incidence variations, risk factors, and preventive measures. The limited number of cancer studies conducted in Afghanistan highlights the importance of the present review. This article provides an overview of cancer burden in Afghanistan in 2020. It utilizes IARC-generated GLOBOCAN 2020 data for one, three, and five-year prevalence rates, the estimated number of new cancer cases, and mortality rates by age group in Afghanistan. According to GLOBOCAN, the top five common cancers in both sexes in Afghanistan were breast (n = 3173, 14.3%), stomach (n = 2913, 7.8%), lung (n = 1470, 6.6%), cervix uteri (n = 1200, 5.4%), and colorectum (n = 1084, 4.9%). This study provides a brief overview of the general cancer situation in Afghanistan, and a more in-depth analysis of the five common cancers identified. Effective therapies, awareness, and prevention initiatives targeting lifestyle, immunization, early diagnosis, and environmental risk factors are essential for addressing the impact of population growth and aging on cancer incidence in Afghanistan. Further research and extensive studies are needed to better understand cancer burden in the country.
Sections du résumé
BACKGROUND
Afghanistan is in an epidemiological transition, as cancer is the second leading cause of mortality due to non-communicable diseases. This study is the first to provide a comprehensive perspective on the overall cancer situation in Afghanistan by discussing the top five most common cancers, their incidence variations, risk factors, and preventive measures. The limited number of cancer studies conducted in Afghanistan highlights the importance of the present review.
RECENT FINDINGS
This article provides an overview of cancer burden in Afghanistan in 2020. It utilizes IARC-generated GLOBOCAN 2020 data for one, three, and five-year prevalence rates, the estimated number of new cancer cases, and mortality rates by age group in Afghanistan. According to GLOBOCAN, the top five common cancers in both sexes in Afghanistan were breast (n = 3173, 14.3%), stomach (n = 2913, 7.8%), lung (n = 1470, 6.6%), cervix uteri (n = 1200, 5.4%), and colorectum (n = 1084, 4.9%).
CONCLUSION
This study provides a brief overview of the general cancer situation in Afghanistan, and a more in-depth analysis of the five common cancers identified. Effective therapies, awareness, and prevention initiatives targeting lifestyle, immunization, early diagnosis, and environmental risk factors are essential for addressing the impact of population growth and aging on cancer incidence in Afghanistan. Further research and extensive studies are needed to better understand cancer burden in the country.
Identifiants
pubmed: 37574721
doi: 10.1002/cnr2.1873
pmc: PMC10480416
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1873Informations de copyright
© 2023 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
Arch Iran Med. 2021 Jul 01;24(7):556-567
pubmed: 34488321
J Natl Cancer Inst. 2015 Nov 07;108(2):
pubmed: 26547931
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Int J Cancer. 1995 Jan 3;60(1):1-26
pubmed: 7814140
J Natl Cancer Inst. 2013 Apr 17;105(8):526-35
pubmed: 23543779
Vaccine. 2020 Feb 5;38(6):1352-1362
pubmed: 31870571
Int Health. 2021 Jan 14;13(1):3-12
pubmed: 32304214
Ann Intern Med. 2011 Nov 15;155(10):698-705, W216
pubmed: 22006929
Nutr Cancer. 2022;74(2):463-471
pubmed: 33560151
Eur J Cancer Prev. 2018 Mar;27(2):124-133
pubmed: 27560662
Acta Med Croatica. 2010 May;64(2):159-61
pubmed: 20649083
Aliment Pharmacol Ther. 2004 Jul;20 Suppl 1:17-24
pubmed: 15298601
Iran J Public Health. 2022 Feb;51(2):306-317
pubmed: 35866136
Indian J Surg Oncol. 2020 Sep;11(3):344-347
pubmed: 33013108
Front Public Health. 2023 Feb 22;11:982416
pubmed: 36908476
Lancet Oncol. 2022 May;23(5):562-563
pubmed: 35489336
Best Pract Res Clin Gastroenterol. 2015 Dec;29(6):895-905
pubmed: 26651251
EClinicalMedicine. 2021 Jul 07;38:100985
pubmed: 34278281
Lancet Infect Dis. 2023 Feb;23(2):141-142
pubmed: 36610440
J Oncol. 2012;2012:121873
pubmed: 22956949
Int J Cancer. 2009 Jul 15;125(2):253-6
pubmed: 19384945
Int Q Community Health Educ. 2020 Apr;40(3):219-236
pubmed: 31488039
Nutr Cancer. 2022;74(7):2489-2498
pubmed: 34894928
Int J Cancer. 2021 Apr 5;:
pubmed: 33818764
Women Health. 2004;39(3):63-77
pubmed: 15256356
Front Reprod Health. 2021 Dec 09;3:783271
pubmed: 36303966
Subst Abuse Treat Prev Policy. 2023 Jan 22;18(1):7
pubmed: 36683028
Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2287-97
pubmed: 20699372
Int J Cancer. 2016 May 15;138(10):2415-27
pubmed: 26756677
Int J Cancer. 2017 Aug 15;141(4):664-670
pubmed: 28369882
Dig Liver Dis. 2017 Jul;49(7):742-749
pubmed: 28495503
CA Cancer J Clin. 2020 Jul;70(4):245-271
pubmed: 32515498
Heliyon. 2020 Mar 20;6(3):e03603
pubmed: 32258464
Tob Control. 2012 Mar;21(2):96-101
pubmed: 22345230
Environ Health Perspect. 2014 Sep;122(9):906-11
pubmed: 24911630
Bull World Health Organ. 2001;79(10):954-62
pubmed: 11693978
World J Gastroenterol. 2018 Jul 14;24(26):2818-2832
pubmed: 30018477
BMC Cancer. 2021 Jan 15;21(1):71
pubmed: 33446123
PLoS One. 2021 Dec 10;16(12):e0261238
pubmed: 34890415
Int J Cancer. 1967 May 15;2(3):269-79
pubmed: 6041994
Int J Cancer. 2020 Aug 1;147(3):811-819
pubmed: 32020598
Semin Oncol Nurs. 2019 Apr;35(2):166-174
pubmed: 30878194
Int J Cancer. 2016 Dec 1;139(11):2436-46
pubmed: 27522007
Chin J Cancer Res. 2020 Dec 31;32(6):683-694
pubmed: 33446992
Asian Pac J Cancer Prev. 2022 Oct 01;23(10):3273-3279
pubmed: 36308349
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Cancer Rep (Hoboken). 2023 Sep;6(9):e1873
pubmed: 37574721
Milbank Mem Fund Q. 1971 Oct;49(4):509-38
pubmed: 5155251
BMC Public Health. 2019 Nov 27;19(1):1581
pubmed: 31775697
Gastroenterology. 2015 Apr;148(4):719-31.e3
pubmed: 25655557
Cancer Epidemiol Biomarkers Prev. 2014 Jun;23(6):1025-36
pubmed: 24836468
Cancers (Basel). 2021 Aug 25;13(17):
pubmed: 34503097
MMWR Morb Mortal Wkly Rep. 2011 Sep 16;60(36):1243-7
pubmed: 21918494
Prz Gastroenterol. 2019;14(1):26-38
pubmed: 30944675
J Nutr Metab. 2012;2012:436762
pubmed: 22720142
Int J Cancer. 2015 Jan 15;136(2):487-90
pubmed: 24889903
Iran J Cancer Prev. 2016 Feb 23;9(1):e5443
pubmed: 27366315
Cancer. 2021 Aug 15;127(16):3029-3030
pubmed: 34086348
Cancer. 1969 Mar;23(3):678-88
pubmed: 5812837
Biomed Pharmacother. 2017 Mar;87:8-19
pubmed: 28040600
Prev Med. 2019 Jun;123:217-224
pubmed: 30940572